All nine macaques given the control developed severe disease when exposed to bird flu, as did all given the smallest dose of ...

The imaging artificial intelligence developer Quibim has raised $50 million in venture capital funding, to support its work ...

Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked ...

Just a few years ago, children with Type 1 diabetes reported to the school nurse several times a day to get a finger pricked ...

The drug in question, called firicabtagene autoleucel or firi-cel, is an autologous CD22 CAR-T cell therapy that had been ...

Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic ...

Takeda has axed plans to seek approval for its failed epilepsy drug candidate soticlestat. The Japanese drugmaker pulled the ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

Sanofi has removed a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers of Ablynx, ...

Mab’s pipeline pivot had a sting in the tail. Weeks after shifting its focus, the biotech said Wednesday that it has reduced ...

Stryker is selling off its spine implant business—starting with a plan to spin off its U.S. operations before moving on to ...

Zimmer Biomet is taking steps to expand its foot and ankle orthopedics business with a $1.1 billion deal to acquire ...